A comparison of the efficacy and safety of buserelin vs danazol in the treatment of endometriosis. Protocol 310 Study Group

M Y Dawood, Dawood MY, Spellacy Wn, W N Spellacy, W P Dmowski, Dmowski WP, W. Paul Dmowski, R D Gambrell, Gambrell Rd, Gambrell RD Jr, Greenblatt Rb, R. B. Greenblatt, Girard Y, Y Girard, A. Lemay, Lemay A, D R Mishell, Mishell DR Jr, Mishell Dr, M Nagamani, Manubai Nagamani, Nagamani M, Pepperell RJ, R. J. Pepperell
Progress in clinical and biological research · 1990 · vol. 323 , pp. 253–67 · PMID:2106142 · W2413537123
Other OA: closed CC0 ⤵ 12 in-corpus citations
Limited metadata. Only one source feed has indexed this record so far — no abstract, full text, or open-access copy is available through Endo Lab. The publisher is the canonical location for the actual content. If you have institutional access, use "Find at my library".
View on OpenAlex View on PubMed
⚙ AI-generated summary by gemini-2.5-flash-lite, 2026-06-06 ⓘ

This study compared the efficacy and safety of buserelin to danazol for treating endometriosis.

One-sentence paraphrase of the abstract; not a substitute for reading it. No clinical advice. How this works

My notes (saved in your browser only)

Condition tags

endometriosis

MeSH descriptors

Buserelin Danazol Endometriosis Pregnadienes Adult Adult Buserelin Buserelin Buserelin Climacteric Climacteric Climacteric Clinical Protocols Clinical Protocols Danazol Danazol Danazol Endometriosis Endometriosis Endometriosis

Citation neighborhood (2-hop)

Papers in the corpus that this work cites (lower rings, blue) and that cite this one (upper rings, green). Dot size scales with the paper's in-corpus citation count — bigger dot = more influential within the endo/adeno field. Click a dot to open that paper. Outer rings show 2-hop neighbours — papers reached through the immediate citers/citees. [ collapse to 1-hop ]

Cited by (12)

Source provenance

europepmc
last seen: 2026-10-18T09:30:06.152893+00:00
openalex
last seen: 2026-06-10T17:14:06.276822+00:00
pubmed
last seen: 2026-10-08T21:08:15.389298+00:00
License: CC0 · commercial use OK